MediciNova Announces Abstract Regarding MN-166 ( ibudilast ) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - MediciNova ( NASDAQ:MNOV )

a week ago

LA JOLLA, Calif., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , today announced that an abstract regarding a clinical trial of MN-166 ( ...

Ticker	Sentiment	Impact
MNOV	Neutral	34 %